Refractory Gout Study
If you have hard-to-treat, or refractory, gout consider joining the DISSOLVE II clinical research study.
- Current treatments for refractory gout often cause an unwanted immune response.
- This can reduce their effectiveness and may lead to serious side effects.
- SEL-212 is the first investigational drug designed to treat refractory gout AND prevent an immune response.
About the Clinical Research Study
- Study participants who test positive for COVID-19 will receive at NO COST:
- Outpatient study-related care that includes follow-up COVID-19 testing.
- Compensation for study-related time and reimbursement for travel.
- Opportunity to support COVID-19 research.
The DISSOLVE II Study will assess whether a once-monthly infusion of SEL-212 could help manage the symptoms of gout more effectively over a longer period.
If you are interested in taking part in the DISSOLVE II Study, we are searching for people who:
- Are 19–80 years of age (women must not be able to have children)
- Have ongoing symptoms of gout despite treatment
- Have experienced 3 or more gout flare-ups within the last 18 months, OR have gouty arthritis OR gout tophi
*There are other criteria that you will need to meet to qualify, which the study team will discuss with you.